IVAWe are retracing to the 200 Ma which also happens to be the 1.272 fib. this offers a short opportunity of 8.57%.
Nothing I say is financial advice.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.33 USD
−199.26 M USD
9.95 M USD
94.03 M
About INVENTIVA
Sector
Industry
CEO
Frédéric Cren
Website
Headquarters
Daix
Founded
2011
FIGI
BBG00VM4C335
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
Possibility of strong rise, but beware of speculatorsThis increase of more than 30% of November 1 is not obtained as a result of news concerning Inventiva, caution, therefore, following the speculators who can in the short term vary the action.
In the long run, I think it's a big possibility if the products work and the tests succeed one after the ot
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.